| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales - EUR | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Income - EUR | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Expenses - EUR | 3.483 | 4.173 | 4.842 | 0 | 0 | 0 | 0 | 0 | 0 | 546 |
| Gross Profit/Loss - EUR | -3.483 | -4.173 | -4.842 | 0 | 0 | 0 | 0 | 0 | 0 | -546 |
| Net Profit/Loss - EUR | -3.483 | -4.173 | -4.842 | 0 | 0 | 0 | 0 | 0 | 0 | -546 |
| Employees | 1 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Check the financial reports for the company - Canamed Pharma S.r.l.
| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Fixed Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Current Assets | -166 | -97 | -248 | -244 | -239 | -234 | -229 | -230 | 0 | -223 |
| Inventories | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Receivables | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 23 |
| Cash | -166 | -97 | -248 | -244 | -239 | -234 | -229 | -230 | 0 | -246 |
| Shareholders Funds | -15.219 | -19.237 | -23.753 | -23.318 | -22.866 | -22.432 | -21.935 | -22.003 | 0 | -22.360 |
| Social Capital | 45 | 45 | 44 | 43 | 42 | 41 | 40 | 41 | 0 | 40 |
| Debts | 15.053 | 19.141 | 23.505 | 23.074 | 22.627 | 22.198 | 21.706 | 21.773 | 0 | 22.136 |
| Income in Advance | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Exchange rate - RON | 4.9743 | 4.9465 | 4.9315 | 4.9468 | 4.8371 | 4.7454 | 4.6535 | 4.5681 | 4.4908 | 4.445 |
| Main CAEN | "4939 - 4939" | |||||||||
| CAEN Financial Year |
4939
|
|||||||||
Comments - Canamed Pharma S.r.l.